PVRIG Inhibitors
Chemical inhibitors of PVRIG can exert their inhibitory effects through various mechanisms that ultimately reduce the functional activity of PVRIG as part of the immune checkpoint regulation. Rapamycin forms a complex with FKBP12 that inhibits mTOR, a kinase integral to T-cell proliferation, thereby indirectly decreasing the need for PVRIG's inhibitory action on these cells. PD-98059 and U0126 target the MEK enzymes in the MAPK pathway, reducing ERK activity which is crucial for T-cell function; this results in a decreased reliance on PVRIG's function. Wortmannin and LY294002 both directly inhibit PI3K, a kinase involved in T-cell activation, leading to a reduced functional necessity for PVRIG in the regulation of T-cell responses.
Further along these lines, SP600125 inhibits JNK which attenuates T-cell activation, thus lessening the significance of PVRIG's role in T-cell suppression. SB203580 targets p38 MAPK, affecting cytokine production and T-cell differentiation, which consequently reduces the functional importance of PVRIG in immune responses. Dasatinib, a multi-tyrosine kinase inhibitor, dampens T-cell activation by inhibiting kinases involved in T-cell activation pathways, while Sunitinib and Imatinib inhibit receptor tyrosine kinases that are essential for T-cell function and activation, resulting in a decreased requirement for PVRIG's control over T-cell responses. Lastly, PP2, by inhibiting Src family tyrosine kinases that contribute to T-cell receptor signaling, leads to subdued T-cell activity, which in turn diminishes the functional significance of PVRIG in the modulation of immune responses. Each of these chemical inhibitors targets specific kinases or pathways that are central to T-cell activation and function, which are the very processes where PVRIG exerts its regulatory effects, thus achieving functional inhibition.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin binds to FKBP12 and the complex inhibits mTOR, a kinase important in T-cell proliferation. Inhibiting mTOR would reduce T-cell activity, thus reducing the functional necessity for PVRIG's inhibitory action on those cells. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD-98059 inhibits MEK, which is upstream of ERK in the MAPK pathway. Since PVRIG is implicated in T-cell signaling, inhibition of this pathway would decrease T-cell response and thereby lessen the functional demand for PVRIG. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 inhibits MEK1/2, leading to downregulation of the MAPK/ERK pathway, which is crucial for T-cell function and activation. The downregulation of this pathway reduces the requirement for PVRIG's role in T-cell suppression. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent PI3K inhibitor, which is involved in T-cell activation. By inhibiting PI3K, the activity of T-cells is reduced, which would decrease the functional significance of PVRIG in immune checkpoint regulation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor that prevents T-cell activation by blocking the PI3K/Akt pathway, thereby reducing the functional necessity of PVRIG in controlling T-cell responses. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, which is part of the signaling pathways in T-cells. By inhibiting JNK, T-cell activation is reduced, thus diminishing PVRIG's role in T-cell suppression. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 inhibits p38 MAPK, which is involved in cytokine production and T-cell differentiation. Inhibition of p38 MAPK would limit T-cell responses, thereby reducing the functional importance of PVRIG in the immune system. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib inhibits multiple tyrosine kinases, including those involved in T-cell activation. By inhibiting these kinases, T-cell activity is diminished, which in turn decreases the functional relevance of PVRIG. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib inhibits receptor tyrosine kinases that are involved in T-cell activation and function. The inhibition of these kinases lessens T-cell activity, thereby reducing the functional requirement for PVRIG. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib inhibits certain tyrosine kinases that play roles in T-cell activation. By blocking these kinases, T-cell mediated responses are downregulated, which decreases the functional need for PVRIG in immune checkpoints. | ||||||